



PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Application Number	10/674,836
Filing Date	September 29, 2003
First Named Inventor	Gregg B. MORIN
Art Unit	1635
Examiner Name	Jon E. ANGELL
Attorney Docket Number	082/103

Sheet 1 of 2

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number-Kind-Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind-Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear	T
/JEA/		WO 00/46355 A2	08-10-2000	Geron Corporation		

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Trans
/JEA/		AGHI, M. & MARTUZA, R., "Oncolytic viral therapies – the clinical experience," <i>Oncogene</i> 24:7802-16 (2005).	
		EBERT, O. et al., "Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice," <i>Cancer Gene Therapy</i> 12:350-58 (2005).	
		GU, J. & FANG, B., "Telomerase Promoter-Driven Cancer Gene Therapy," <i>Cancer Biol. Ther.</i> 2:4(Suppl. 1):S64-S70 (2003).	
		GU, J. et al., "Tumor-specific Transgene Expression from the Human Telomerase Reverse Transcriptase Promoter Enables Targeting of the Therapeutic Effects of the Bax Gene to Cancers," <i>Cancer Res.</i> 60:5359-64 (2000).	
		IRVING, J. et al., "Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity," <i>Cancer Gene Therapy</i> 11:174-85 (2004).	
		JACOB, D. et al., "Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter," <i>Cancer Gene Therapy</i> 12:109-15 (2005).	
		LI, X. et al., "Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis," <i>J. Gene Med.</i> 8:679-89 (2006).	
		LUI, V. et al., "Systemic Administration of Naked DNA Encoding Interleukin 12 for the Treatment of Human Papillomavirus DNA-Positive Tumor," <i>Human Gene Therapy</i> 13:177-85 (2002).	
/JEA/		MAJUMDAR, A. et al., "The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters," <i>Gene Therapy</i> 8:568-78 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	11/471,916
		Filing Date	June 20, 2006
		First Named Inventor	Joseph D. Gold
		Art Unit	1636
		Examiner Name	Not Yet Assigned
Sheet	2	of	2
		Attorney Docket Number	099/041

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Trans
/JEA/		PRADOS, M. et al., "Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial," <i>J. Neuro-Oncology</i> 65:269-78 (2003).	
/JEA/		WIRTH, T. et al., "A Telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer," <i>Cancer Res.</i> 63:3181-88 (2003).	
/JEA/		WU, X. et al., "Systemic administration of naked DNA with targeting specificity to mammalian kidneys," <i>Gene Therapy</i> 12:477-86 (2005).	

Examiner Signature	/Jon Eric Angell/	Date Considered	04/16/2007
-----------------------	-------------------	--------------------	------------